Keymed Biosciences Inc.
2162.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$23.07B
Close$
Share Statistics
| Market cap | $23.07 Billion |
|---|---|
| Enterprise Value | $21.42 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.86 |
| Beta | -0.15 |
| Outstanding Shares | 283,506,861 |
Return
| Return on Equity | 12.66% |
|---|---|
| Return on Assets | 8.94% |
| Return on Invested Capital | -20.21% |
Valuation & Multiples
| P/E Ratio | 23.98 |
|---|---|
| PEG | -1.48 |
| Price to Sales | 15.66 |
| Price to Book Ratio | 5.59 |
| Enterprise Value to Revenue | 12.64 |
| Enterprise Value to EBIT | -21.84 |
| Enterprise Value to Net Income | 42 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.18 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$5.31
Average shareholder expectationRevenue Estimate
$710.74 M
Average shareholder expectationNext Earnings Call
Expected Date
March 30, 2027
EPS Estimate
$-0.66
Average shareholder expectationRevenue Estimate
$650.17 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Keymed Biosciences Inc.
1,768 employees
CEO: Bo Chen Keymed Biosciences Inc., a biotechnology firm founded in 2016 in Chengdu, China (formerly known as 2Health Biosciences, Inc.), specializes in the research and development of innovative biological treatments, primarily targeting autoimmun...